Ghost Tree Capital’s Fate Therapeutics FATE Stock Holding History

Ghost Tree Capital’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-50,000	Closed	-$2.96M	–	57
2021 Q3	$2.96M	Sell	50,000 -135,000	-73%	-$10.6M	0.87%	43
2021 Q2	$16.1M	Hold	185,000	–	–	4.41%	4
2021 Q1	$15.3M	Buy	185,000 +20,000	+12%	+$1.92M	3.58%	8
2020 Q4	$15M	Sell	165,000 -35,000	-18%	-$2.17M	3.34%	11
2020 Q3	$7.99M	Buy	200,000 +75,000	+60%	+$2.62M	2.31%	15
2020 Q2	$4.29M	Sell	125,000 -100,000	-44%	-$2.98M	1.13%	29
2020 Q1	$5M	Sell	225,000 -50,000	-18%	-$1.26M	1.33%	18
2019 Q4	$5.38M	Sell	275,000 -75,000	-21%	-$1.19M	1.02%	31
2019 Q3	$5.44M	Buy	+350,000	New	+$6.71M	1.39%	23
2018 Q4	–	Sell	-75,000	Closed	-$1.22M	–	49
2018 Q3	$1.22M	Buy	+75,000	New	+$887K	0.26%	48
2015 Q4	–	Sell	-89,231	Closed	-$476K	–	58
2015 Q3	$476K	Buy	+89,231	New	+$609K	0.21%	66

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ghost Tree Capital's FATE Position: Q4 2021 in Review

Ghost Tree Capital sold out of Fate Therapeutics (FATE) in Q4 2021, closing a stake of 50,000 shares — an estimated $2.96M sold.

Ghost Tree Capital first reported a position in FATE in Q3 2015 and held it in 11 quarters. The position peaked at $16.1M in Q2 2021. 250 funds tracked by Wall St. Rank hold FATE as of Q4 2021.

Ghost Tree Capital reported no remaining Fate Therapeutics position as of Q4 2021 after selling out during the quarter.
Ghost Tree Capital sold 50,000 Fate Therapeutics shares in Q4 2021, an estimated $2.96M.
Ghost Tree Capital first reported a position in Fate Therapeutics in Q3 2015 and held it in 11 quarters.
Ghost Tree Capital's Fate Therapeutics position peaked at $16.1M in Q2 2021.
250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2021.

Based on Ghost Tree Capital's 13F filing for Q4 2021, filed 16 Feb 2022.